These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 7835802)

  • 21. Expanding the public health research agenda for ovarian cancer.
    Trivers KF; Stewart SL; Peipins L; Rim SH; White MC
    J Womens Health (Larchmt); 2009 Sep; 18(9):1299-305. PubMed ID: 19702475
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New advances in screening and treatment of ovarian cancer].
    Morice P; Pautier P; Bidart JM
    Bull Cancer; 2003 Jan; 90(1):53-60. PubMed ID: 12609805
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Making decisions about screening for ovarian cancer. Mass screening may not prove to be sound public health policy.
    Bell R
    BMJ; 2000 Apr; 320(7239):940; author reply 940-1. PubMed ID: 10787261
    [No Abstract]   [Full Text] [Related]  

  • 24. Gene therapy for ovarian cancer (review).
    Wolf JK; Jenkins AD
    Int J Oncol; 2002 Sep; 21(3):461-8. PubMed ID: 12168087
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Family physicians' perspectives on ovarian cancer.
    Gray RE; Chart P; Carroll JC; Fitch MI; Cloutier-Fisher D
    Cancer Prev Control; 1999 Feb; 3(1):61-7. PubMed ID: 10474754
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of a cancer risk assessment clinic.
    Med Manag Netw; 1999 Jul; 7(7):6-10. PubMed ID: 10538699
    [No Abstract]   [Full Text] [Related]  

  • 27. Early cancer detection programmes for women at high risk for breast and ovarian cancer: a proposal of practical guidelines.
    Beckmann MW; Schnürch HG; Bodden-Heidrich R; Mosny DS; Crombach G; Nitz U; Achnoula M; Bender HG
    Eur J Cancer Prev; 1996 Dec; 5(6):468-75. PubMed ID: 9061278
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Screening for ovarian cancer: recommendations and rationale. American College of Physicians.
    Ann Intern Med; 1994 Jul; 121(2):141-2. PubMed ID: 8017728
    [No Abstract]   [Full Text] [Related]  

  • 29. Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer.
    Tiller K; Meiser B; Gould L; Tucker K; Dudding T; Franklin J; Friedlander M; Andrews L
    Psychooncology; 2005 Apr; 14(4):249-61. PubMed ID: 15386771
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical management of BRCA1 and BRCA2 mutation carriers.
    Domchek SM; Weber BL
    Oncogene; 2006 Sep; 25(43):5825-31. PubMed ID: 16998496
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The biology of ovarian cancer of epithelial origin.
    Rabinerson D; Kaplan B; Levavi H; Neri A
    Isr J Med Sci; 1996 Nov; 32(11):1128-33. PubMed ID: 8960089
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [INSERM-FNCLCC collective expertise. Recommendations for medical management of women with genetic risk of developing breast and/or ovarian cancer].
    Eisinger F; Alby N; Bremond A; Dauplat J; Espié M; Janiaud P; Kuttenn F; Lebrun JP; Lefranc JP; Pierret J; Sobol H; Stoppa-Lyonnet D; Thouvenin D; Tristant H; Feingold J
    Ann Genet; 1999; 42(1):51-64. PubMed ID: 10214508
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for ovarian cancer: not worthwhile for most patients.
    Wong JG; Feussner JR
    N C Med J; 1993 Sep; 54(9):438-40. PubMed ID: 8232615
    [No Abstract]   [Full Text] [Related]  

  • 34. [Problems in the organization of an anticancer campaign among women working for the October Railroad].
    Ugriumova RP
    Vopr Onkol; 1966 Apr; 12(4):87-90. PubMed ID: 6001006
    [No Abstract]   [Full Text] [Related]  

  • 35. 3rd International Ovarian Cancer Consensus Conference: outstanding issues for future consideration.
    Stuart G; Avall-Lundqvist E; du Bois A; Bookman M; Bowtell D; Brady M; Casado A; Cervantes A; Eisenhauer E; Friedlaender M; Fujiwara K; Grenman S; Guastalla JP; Harper P; Hogberg T; Kaye S; Kitchener H; Kristensen G; Mannel R; Meier W; Miller B; Oza A; Ozols R; Parmar M; Pfisterer J; Poveda A; Provencher D; Pujade-Lauraine E; Quinn M; Randall M; Rochon J; Rustin G; Sagae S; Stehman F; Trimble E; Thigpen T; Vasey P; Vergote I; Verheijen R; Vermorken J; Wagner U; ; ; ; ; ; ; ; ; ; ; ; ;
    Ann Oncol; 2005; 16 Suppl 8():viii36-viii38. PubMed ID: 16239235
    [No Abstract]   [Full Text] [Related]  

  • 36. Genetic risk in ovarian cancer.
    Semrad N
    Gynecol Oncol; 1993 Jul; 50(1):134-5. PubMed ID: 8349157
    [No Abstract]   [Full Text] [Related]  

  • 37. Phases in cancer control: intervention research.
    Cullen JW
    IARC Sci Publ; 1990; (103):1-11. PubMed ID: 2279786
    [No Abstract]   [Full Text] [Related]  

  • 38. Advanced ovarian cancer: 20 years of ovarian cancer treatment.
    Poveda A; Romero I
    Ann Oncol; 2016 Apr; 27 Suppl 1():i72-i73. PubMed ID: 27141077
    [No Abstract]   [Full Text] [Related]  

  • 39. Clinical and laboratory directions for ovarian cancer research.
    Bast RC
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S164-7. PubMed ID: 7835802
    [No Abstract]   [Full Text] [Related]  

  • 40. Research directions in epithelial ovarian cancer.
    Ozols RF
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S168-73. PubMed ID: 7835803
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.